New Molecular Entities (NMEs) & Utilization Characterization

New Molecular Entities Approved in 2010-2015 Duration of Follow Up for New Molecular Entities Approved in 2005, 2006, and 2007 Duration of Follow Up for New Molecular Entities Approved in 2007: A Descriptive Analysis Duration of Follow Up for New Molecular Entities Approved in 2008 and 2009 Duration of Follow Up for New Molecular Entities Approved in 2010, 2012, and 2013 Duration of Follow Up for New Molecular Entities Approved in 2011 Duration of Follow Up for New Molecular Entities Approved in 2014 and 2015 Duration of Follow Up for New Molecular Entities Approved in 2016 Duration of Follow Up for New Molecular Entities Approved in 2017: First Descriptive Analysis Duration of Follow Up for New Molecular Entities Approved in 2017: Second Descriptive Analysis Duration of Follow Up for New Molecular Entities Approved in 2017: Third Descriptive Analysis Duration of Follow Up for New Molecular Entities Approved in 2018: First Descriptive Analysis Duration of Follow Up for New Molecular Entities Approved in 2018: Second Descriptive Analysis Duration of Follow Up for New Molecular Entities Approved in 2019: First Descriptive Analysis Duration of Follow Up for New Molecular Entities Approved in 2019: Second Descriptive Analysis Duration of Follow Up for New Molecular Entities Approved in 2020: First Descriptive Analysis Characterization of Users of New Molecular Entities Approved in 2021 in TriNetX: A Descriptive Analysis Duration of Follow Up for New Molecular Entities Approved in 2021: First Descriptive Analysis Characterization of Users of Atogepant in TriNetX: A Descriptive Analysis Characterization of Users of Inclisiran in TriNetX: A Descriptive Analysis

Presentation: Early Post-Approval Surveillance of New Molecular Entity Uptake in the Sentinel Distributed Database Presentation: Early Uptake of New Molecular Entities Approved in 2017 in a Multisite National US Healthcare Data Network Presentation: Analysis of New Molecular Entity Utilization Patterns using the Sentinel Distributed Database Presentation: Assessing Exposure to Recently Approved Medications to Inform Feasibility for Signal Identification Analyses in the FDA’s Sentinel System Presentation: Pediatric Utilization of New Molecular Entities (NMEs): A Summary of Early Post-Marketing Uptake in the Sentinel Distributed Database